Paragon 28

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.

Earnings data Q1 2024

Paragon 28 reports record Q1 revenue, focuses on profitability improvement

Paragon 28's Q1 2023 earnings call showcased strong revenue growth, particularly in the U.S. and international markets. While profitability improvement is a focus, the company remains confident in its future revenue guidance and upcoming product launches.

Paragon 28 reports 15% Q3 revenue growth amidst supply chain challenges

Paragon 28's Q3 2023 performance reflects strong revenue growth and market traction, despite supply chain challenges. The company's focus on product innovation, surgeon training, and financial flexibility positions it for future success. Anticipated improvements in supply chain disruptions and cash flow indicate positive momentum for the company.

Paragon 28 reports robust revenue growth and innovation in Q4

Paragon 28's Q4 '23 earnings call highlighted strong revenue growth, innovative product launches, and a focus on improving surgical outcomes. Despite EBITDA loss, the company remains optimistic about future growth opportunities and operational improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer (“CFO”) on April 8, 2024.

Appointment of Stephen M. Deitsch as new Chief Financial Officer

Redfin

OTTAWA, Ontario--(BUSINESS WIRE)--NeuroStreet acquires TickBlaze to elevate trading tech, promising transformative solutions in the industry.

NeuroStreet To Transform Trading Technology With Tickblaze Acquisition

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), (“Paragon 28” or “the Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Stephen Deitsch, Chief Financial Officer (“CFO”), has notified the Company of his intent to pursue an opportunity with OrganOx Limited, a commercial stage UK-based medical device company focused on therapeutic applications of isolated organ perfusion. Mr. Deitsch will depart from the C.

Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024

The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.

Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Grappler® R3INFORCE™ Extraosseous Repair System designed to restore stability to the anterior and posterior ligaments surrounding the ankle during fibula fracture repairs and high ankle sprains. Upon determination of syndesmotic instability, the Grappler® R3INFORCE™ Anchors are placed in plate holes or other anatomic locations where pre-loaded suture tape can be routed and tensioned to addr.

Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler® R3INFORCE™ Extraosseous Repair System

Paragon 28, Inc. (FNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?

Paragon 28, Inc. (FNA) Q4 2023 Earnings Call Transcript

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2023 and provided 2024 Net Revenue guidance. Fourth Quarter and Full Year 2023 Financial Results Consolidated net revenue for the fourth quarter of 2023 was $60.6 million, representing 17.6% and 17.3% reported and constant currency gro.

Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the CG 2024 Musculoskeletal Conference on Monday, February 12, 2024, at 1:00 p.m. Pacific Time / 2:00 p.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section.

Paragon 28 to Present at the CG 2024 Musculoskeletal Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call ma.

Paragon 28 To Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy using a minimally invasive (MIS) surgical technique. The system features an outrigger designed for controlled tri-planar correction including translation and derotation of the metatarsal head and adjustment of the distal metatarsal articular angle. Instrumentation is also provided to facilitate a fr.

Paragon 28 Launches PRECISION® MIS Bunion System Offering Surgeons a Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is proud to announce a novel solution in modernizing foot and ankle surgery with the launch of its FJ2000™ Power Console and Burr System designed for a wide range of minimally invasive and open procedures in the foot and ankle. The FJ2000™ Power Console and Burr System is highly versatile and designed for quick and efficient setup at the outset of each procedure. The System has three pre-set options, including a low speed, high tor.

Paragon 28 Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Mister Tendon™ System which allows surgeons to perform a distal cut of the flexor hallucis longus (“FHL”) or flexor digitorum longus (“FDL”) tendon through a minimally invasive incision, harvesting a working length of tendon suitable for tendon transfer procedures. Use of this instrumentation through a minimally invasive approach, is designed to allow for better healing and quicker recovery.

Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023. Preliminary unaudited net revenue for the fourth quarter of 2023 is expected to be in a range of $60.3 to $60.6 million, representing reported growth of approximately 17% to 18% compared to.

Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023

ENGLEWOOD, Co.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is thrilled to announce the launch of the Grappler® Knotless Anchor System and Bridgeline™ Tape, enhancing the Company's position in the fast-growing foot and ankle specific soft tissue market in 2024 and beyond. Both the Grappler® Knotless Anchor System and Bridgeline™ Tape are highly complementary to a broad range of Paragon 28's existing hardware products with several applications spanning multiple foot and ankle indications. The.

Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler® Knotless Anchor System and Innovative Bridgeline™ Tape

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 3:00 p.m. Pacific Time / 4:00 p.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the Company.

Paragon 28 to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.

Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics

Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.

Paragon 28 (FNA) New Staple System Expands Ankle Device Line

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its BEAST™ Cortical Fibers which provide an osteoinductive porous structure for cellular attachment and an osteoinductive potential to aid in cellular differentiation and bone formation. These loose cortical fibers are engineered to complement specific surgical applications in the foot and ankle and are flexible upon hydration allowing for application even in extremely challenging fusion locatio.

Paragon 28 Launches BEAST™ Cortical Fibers Expanding its Biologics Portfolio

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its JAWS™ Great White Staple System which was developed to provide for increased strength and stability of the osteotomy or fusion site when compared to traditional staple systems. The staples feature an ultra-low-profile bridge with increased surface area to enhance stability while minimizing soft tissue irritation. The newly designed staple has 400 times the fatigue life compared to a competit.

Paragon 28 Launches JAWS™ Great White Staple System Further Expanding its Nitinol Staple Offering

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a second trailer to its nationwide mobile lab training program making it even more convenient for the company to facilitate on-site surgeon training and education. Paragon 28's new mobile lab is housed in a 40 foot tractor-trailer which includes a state-of-the-art, 5 station, cadaveric training facility accommodating up to 25 surgeons. The mobile lab will host over 70 training sessions in appr.

Paragon 28 Adds Second Mobile Medical Education Lab Significantly Expanding Upon Wildly Successful Foot and Ankle Surgeon Training Program

Paragon 28, Inc. (NYSE:FNA ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Matthew Brinckman - Senior Vice President, Strategy and IR Albert DaCosta - Chairman and CEO Steve Deitsch - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of America Caitlin Cronin - Canaccord George Sellers - Stephens, Inc. Brandon Vazquez - William Blair Mike Matson - Needham Dave Turkaly - JMP Securities Operator Good afternoon. And welcome to Paragon 28's Third Quarter 2023 Earnings Conference Call.

Paragon 28, Inc. (FNA) Q3 2023 Earnings Call Transcript

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that it has received a new $150 million credit facility from Ares Capital Corporation (“the Facility”) to replace its existing $90 million senior credit facility. The Facility is comprised of up to $100 million in term loans, with $75 million drawn at close, and a $50 million revolving credit fa.

Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2023 and reaffirmed its 2023 net revenue guidance. Third Quarter 2023 and Nine Months Ended September 30, 2023 Financial Results Consolidated net revenue for the third quarter of 2023 was $52.8 million, representing 14.7% and 14.5% reported an.

Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance

Paragon 28, Inc. (FNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

News for Paragon 28 Stock (FNA)